Guggenheim initiated coverage of UroGen Pharma with a Buy rating and $40 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
Questions or Comments about the article? Write to editor@tipranks.com